.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
A large retrospective series of 341 retinoblastoma eyes treated with intra-arterial chemotherapy (IAC) reported five-year globe-salvage estimates of about 74% across the overall cohort. The study included more than 1,200 infusions using agents such as melphalan, topotecan, and carboplatin, providing substantial clinical experience with IAC as a primary or secondary globe-preserving strategy. For ocular oncology teams, the publication illustrates how treatment selection is driven by tumor classification, eye-specific disease severity, prior treatment, and the feasibility of preserving a functional globe. IAC has become an important component of multimodal retinoblastoma management, but systemic evaluation and coordinated care remain essential. Outcomes are not uniform across tumor stages, and globe salvage is not synonymous with normal vision. The study is therefore most useful as evidence that IAC can achieve meaningful control and preservation in appropriately selected eyes, while reminding clinicians that long-term surveillance for recurrence, vitreous seeds, vascular complications, and visual development remains part of the care pathway. The data can inform counseling without implying that one modality should replace all other treatment strategies.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A large retrospective series of 341 retinoblastoma eyes treated with intra-arterial chemotherapy (IAC) reported five-year globe-salvage estimates of about 74% across the overall cohort. The study included more than 1,200 infusions using agents such as melphalan, topotecan, and carboplatin, providing substantial clinical experience with IAC as a primary or secondary globe-preserving strategy. For ocular oncology teams, the publication illustrates how treatment selection is driven by tumor classification, eye-specific disease severity, prior treatment, and the feasibility of preserving a functional globe. IAC has become an important component of multimodal retinoblastoma management, but systemic evaluation and coordinated care remain essential. Outcomes are not uniform across tumor stages, and globe salvage is not synonymous with normal vision. The study is therefore most useful as evidence that IAC can achieve meaningful control and preservation in appropriately selected eyes, while reminding clinicians that long-term surveillance for recurrence, vitreous seeds, vascular complications, and visual development remains part of the care pathway. The data can inform counseling without implying that one modality should replace all other treatment strategies.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
